Clozapine-induced agranulocytosis

Area of Science:

• Pharmacology
• Hematology
• Psychiatry

Background:

• Clozapine is a highly effective antipsychotic for treatment-resistant schizophrenia.
• Its use is restricted due to the risk of agranulocytosis, a serious adverse effect.
• Mandatory blood count monitoring is required during clozapine treatment.

Purpose of the Study:

• To review the epidemiology, genetic risk factors, and preventive measures for clozapine-induced agranulocytosis (CLIA).
• To discuss the pathogenesis and clinical management of CLIA.
• To highlight the importance of recognizing benign ethnic neutropenia in Black patients receiving clozapine.

Main Methods:

• Literature review of epidemiology, genetics, pathogenesis, and clinical management of CLIA.
• Discussion of preventive strategies and re-challenge protocols.
• Consideration of ethnic variations in neutropenia, specifically benign ethnic neutropenia.

Main Results:

• CLIA affects up to 0.8% of patients, posing a significant clinical challenge.
• Advances in identifying genetic risk factors for CLIA are emerging.
• Effective management strategies and preventive measures can mitigate CLIA risk.

Conclusions:

• CLIA remains a critical concern limiting clozapine's broader application.
• Further research into CLIA pathogenesis is needed.
• Collaborative management between hematologists and psychiatrists is essential for optimizing clozapine therapy and patient safety, considering ethnic factors.